Objectives: To describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children and evaluate the adequacy of steady-state exposures.
Introduction
Tuberculosis is the most frequent infectious cause of death worldwide with high impact in developing countries. 1 In high-burden settings, children comprise 15% -20% of tuberculosis cases. 2 Young children (,5 years of age) and children with HIV infection are prone to rapid progression to tuberculosis disease following infection and frequently experience severe forms of tuberculosis, including disseminated disease and meningitis. 2 Isoniazid and rifampicin are important for their bactericidal activity against metabolically active Mycobacterium tuberculosis. The sterilizing activities of pyrazinamide and rifampicin prevent the relapse of disease after treatment. 3, 4 Isoniazid plays an important role in preventing the development of resistance to companion drugs such as rifampicin. 5 Dosages of rifampicin higher than those currently employed have been suggested to improve efficacy. 6 Until recently, the daily dosages of first-line antituberculosis drugs recommended in children were derived from the adult dosage based on the assumption that the same dose per kg is appropriate across all ages of patients. Even though rifampicin, isoniazid and pyrazinamide have been available for many years, the limited pharmacokinetic information in children suggests that young children receiving adult-derived dosages have drug exposures lower than adults. 7 -9 In children, factors such as maturation of metabolizing enzymes and transporters, body composition, organ function, nutritional status and the pathophysiology of severe forms of tuberculosis may contribute to changes in pharmacokinetics, drug response and toxicity. 10 Previous studies have reported reduced tuberculosis drug concentrations in adults with HIV infection, 11 but the effect of HIV infection on the pharmacokinetics of tuberculosis drugs has not been adequately evaluated in children. The WHO has recently recommended increased dosages of first-line antituberculosis drugs for children, 12 which are to be implemented using dispersible fixed-dose combination (FDC) tablets for paediatric use, manufactured according to newly recommended specifications, with each tablet containing 50 mg of isoniazid, 75 mg of rifampicin and 150 mg of pyrazinamide. 13 In this paper, we describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in non-linear mixed-effects models, using previously published data from children with tuberculosis aged 2 months to 11.3 years who were given a wide range of dosages. 7, 8, 14, 15 In addition, we used our final models to predict the steady-state area under the concentration -time curve (AUC) and maximum plasma concentration (C max ) in a paediatric population and compared them with the corresponding pharmacokinetic measures in ethnically similar adults with tuberculosis.
Patients and methods

Patient population
Combined data of 76 children obtained from previously published studies describing the plasma concentrations of rifampicin, pyrazinamide and isoniazid in two cohorts of South African children with tuberculosis were used for analysis. 7, 8, 14, 15 On the basis of analysis of genetic polymorphisms of the arylamine N-acetyltransferase 2 (NAT2) gene, the children were categorized as slow-, intermediate-or fast-acetylator genotypes for acetylation of isoniazid. The methods used in the classification of NAT2 genotypes have been previously described for Cohort 1 9 and Cohort 2.
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The demographic and clinical characteristics of all the children are summarized in Table 1 .
Patient treatment and pharmacokinetic sampling
Daily doses of rifampicin and isoniazid were given for 6 months with pyrazinamide added for the first 2 months. Dispersible FDC tablets formulated for children were used 7, 8, 14, 15 and details about the dosing are included in Table 1 . In Cohort 1, the median daily doses of rifampicin, pyrazinamide and isoniazid approximated 10, 23 and 5 mg/kg, respectively. In Cohort 2, on the first pharmacokinetic occasion, the median daily doses were similar to Cohort 1: 10 mg/kg for rifampicin, 25 mg/kg for pyrazinamide and 5 mg/kg for isoniazid. For the second pharmacokinetic occasion, the doses were adjusted, so the median values increased: 15 mg/kg for rifampicin, 36 mg/kg for pyrazinamide and 10 mg/kg for isoniazid. For Cohort 1, blood sampling for pharmacokinetic analysis was conducted at 1 and 4 months after starting treatment. At each sampling occasion, venous blood was drawn at 0.75, 1.5, 3, 4 and 6 h post-dose. Cohort 2 underwent pharmacokinetic sampling ≥2 weeks after initiation of antituberculosis therapy and sampling was repeated 1 week later, with samples drawn pre-dose and at 0.5, 1.5, 3 and 5 h after the dose. Cohort 1 plasma concentrations of rifampicin, pyrazinamide and isoniazid were determined by liquid chromatography -tandem mass spectrometry (LC/MS/MS) as detailed previously. 7, 14, 16 The lower limit of quantification (LLOQ) for both rifampicin and isoniazid was 0.1 mg/L and for pyrazinamide was 0.2 mg/L. In Cohort 2, isoniazid and pyrazinamide plasma concentrations were determined by HPLC and UV detection, 15 whereas rifampicin was determined by LC/MS/MS. 15 The lower limit of detection (LLOD) in Cohort 2, under which no concentration was reported, was 0.25, 0.5 and 0.15 mg/L for rifampicin, pyrazinamide and isoniazid, respectively. Moreover, the assay could not guarantee 5% precision between the LLOD (0.75, 1.5 and 1 mg/L for rifampicin, pyrazinamide and isoniazid, respectively) and LLOQ values. 
Pharmacokinetic data analysis
The concentration -time data for each drug were analysed separately using a non-linear mixed-effects approach. The estimation of typical population pharmacokinetic parameters, along with their random interindividual variability (IIV) and inter-occasional variability (IOV), was performed in NONMEM7 (Icon Development Solutions, Ellicott City, MD, USA) 17 using a first-order conditional estimation method with 1-h interaction (FOCE INTER). 18 For all three drugs (rifampicin, pyrazinamide and isoniazid), model development was carried out first by developing the structural and stochastic model, including allometric scaling, and then investigating covariate effects. Graphical diagnostics were created using Xpose 4. 19 In all models, allometric scaling was applied on the oral clearance (CL) and apparent volume of distribution in plasma (V c ) according to Anderson and Holford. 20 As reference, the median body weight of 12.5 kg from Cohort 1 ( Table 1 ) was used.
(1)
CL i is the scaled typical value of CL for individual i, CL std is the typical CL for an individual of 12.5 kg and WT i is the body weight of individual i in kg. A similar notation applies to V i . In the case of a two-compartment model, allometric scaling was also applied on the inter-compartmental clearance (Q) (as in Equation 1 ) and on the apparent peripheral volume of distribution (V p ) (as in Equation 2). After allometric scaling was included, the need for including maturation models following the approach previously described by Anderson and Holford 21 was evaluated. The maturation factor (MF) was calculated using Equation 3:
where PMA is age derived by adding 36 weeks to the post-natal age, 22 assuming no premature birth. TM 50 is the age at which maturation reaches 50% of the final value and Hill is the coefficient that regulates the rate of onset of the maturation. Models with and without the Hill factor fixed to 1 were tested. The structural models tested included one-and two-compartment models with first-order elimination. Different absorption models were explored, such as first-order absorption or a sequence of zero-and firstorder absorption incorporating either lag times or transit compartment absorption. 23, 24 The effect of a dose dependency on the pharmacokinetic parameters was also tested. For relative bioavailability (F), first-order absorption rate constant (k a ), mean transit time (MTT) and CL of rifampicin (a substrate of polymorphic OATP1B1 transporter) 25 and isoniazid (a substrate of polymorphic metabolizing enzyme NAT2) the possibility of subpopulations having different parameter estimates was tested using mixture models. A log-normal model for IIV and IOV was used and shrinkage in the post hoc estimates was derived. Additive and/or proportional models for the residual unexplained variability were evaluated. In Cohort 1, the drug concentrations reported as below the LLOQ were 0.6%, 0% and 3.4% for rifampicin, pyrazinamide and isoniazid, respectively. In Cohort 2, the values below the LLOD were 19%, 5.5% and 17.1% for rifampicin, pyrazinamide and isoniazid, respectively. Additionally, 4.5%, 3% and 24.1% of the concentrations of rifampicin, pyrazinamide and isoniazid, respectively, were in the 'low precision' range of the assay, but above the LLOD. The larger proportion of low concentrations in Cohort 2 is partly due to the collection of a pre-dose sample. All the data below the LLOQ in Cohort 1 were handled by fixing the error structure to additive with size LLOQ/2, to include these samples in the fit while accounting for the lower precision. In Cohort 2, values below the LLOD were replaced with LLOD/2, discarding consecutive undetectable concentrations in a series. Moreover, for all LLOD values and the samples in the 'low precision' range of the assay, the error structure was fixed to additive and with size half of the threshold of low precision of the assay, once again to account for the larger uncertainty in these measurements.
The effect of age, sex and HIV infection was tested on F, CL, V c , V p , k a and MTT. Arm muscle area (AMA) was tested as a predictor of CL, V c and V p while albumin and other nutritional status measures (weight-for-age, weight-for-height and height-for-age z scores) were tested on F, CL, V c and V p .
The AMA values were derived from percentiles from the US Health and Nutrition Examination Survey I from 1971 to 1974 26 and the z scores were derived from National Center for Health Statistics/CDC/WHO international reference standards. 27 Missing continuous covariate data were replaced with the individual information from the other dosing and sampling occasion, if available. Otherwise, median values from the cohort were used. Missing categorical covariates were replaced with the most common category, except for acetylator genotype. For the missing genotype data (four individuals), a mixture model was used. The likelihood of belonging to each acetylator status was fixed to the frequency observed in the subjects for whom the information was available.
Potential covariate relationships were identified by clinical and statistical significance. The covariate relationships were tested in the model by stepwise addition (forward step) using a difference in the NONMEM objective function value (DOFV) of ≥3.84 (P≤ 0.05) as the cut-off for inclusion, followed by stepwise deletion (backward step) using DOFV of ≥6.83 (P≤ 0.01) as a requisite for covariate retention.
The effect of continuous covariates was parameterized as shown in Equation 4:
where u p is the parameter (PAR) estimate in a typical patient (a child with median covariate value of COV med ), while u cov is the fractional change in PAR with each unit change in the covariate (COV) from COV med . For categorical covariates, such as acetylator genotype, a separate typical value for the parameter under test was estimated in each group.
Model evaluation
Model selection was based on the graphical assessment of conditional weighted residuals versus time, basic goodness-of-fit plots, changes in the OFV, precision of parameter estimates as provided by the covariance step (if successfully completed) and visual predictive checks (VPCs). 28 
Simulations
Using Monte Carlo simulations, the final models were used to simulate the steady-state AUC and C max for children using pragmatic weight bands (adhering as closely as possible to the revised guidelines in dose per unit weight) 12 using one to four undivided tablets of an FDC with the newly recommended specifications (i.e. 75/50/150 mg of rifampicin/isoniazid/ pyrazinamide in each FDC tablet). 13 The AUC and C max were predicted for children weighing 5.0 -7.9, 8.0 -11.9, 12.0 -15.9 and 16.0 -24.0 kg receiving respective daily doses of one, two, three and four FDC tablets. Individual weight and age values used in the simulations were additionally obtained from historical data of 246 South African children with tuberculosis; 72% were infected with HIV (2% with HIV status unknown) and 54% were males. Pooling these with the present data from the two cohorts (Table 1) , we obtained a dataset of baseline values for 322 children. The pharmacokinetic models were applied (1000 repetitions) to this in silico population, using the WHO-recommended dosing guidelines, and the AUC and C max values were collected for each weight band. To obtain reference values for comparison, previously published pharmacokinetic models 24, 29, 30 from an ethnically similar population of adult patients were used to simulate AUC and C max ranges using the current Population pharmacokinetics of antituberculosis drugs in children 1341 JAC WHO-recommended dosing guidelines for adults. 31 The respective daily doses used for simulations in adults weighing 30.0 -37.9, 38.0 -54.9, 55.0 -69.9 and ≥70 kg were: 300, 450, 600 and 750 mg for rifampicin; 800, 1200, 1600 and 2000 mg for pyrazinamide; and 150, 225, 300 and 375 mg for isoniazid.
Results
Rifampicin
A total of 629 concentration-time data points were available for 67 children. 8, 15 The final pharmacokinetic model for rifampicin was a one-compartment model with transit compartments absorption 23 and first-order elimination. The parameter estimates of the final model are shown in Table 2 . The absorption transit model was simplified by fixing k a to the same value as the firstorder transit rate constant (k tr ), since the two were not significantly different. HIV status, age and albumin levels had no influence on the pharmacokinetics of rifampicin. Age maturation was supported for CL and MTT and resulted in a 23 point improvement in OFV, explaining 16% IIV in CL and 17% IOV in MTT (no IIV in MTT was present in the model). TM 50 was estimated to be 58.2 weeks, which is 22.2 weeks (0.43 years) after birth for both CL and MTT. The proportional change of each parameter with post-natal age is shown in Figure 1 . The final model included IIV, expressed as percentage coefficient of variation (%CV), in CL (33%) and V c (43%), while IOV was significant for CL (25%), F (48%) and MTT (40%). The residual error model had both additive (0.122 mg/L for Cohort 1 and 0.63 mg/L for Cohort 2) and proportional (23% for both cohorts) terms. The final pharmacokinetic model described the data well, as shown in the VPC (Figure 2) . When scaled to a 70 kg individual, the typical values for CL and V c were 29.7 L/h and 90.7 L, respectively.
Pyrazinamide
A total of 518 concentration -time data points were available for 55 children. 14, 15 The final pharmacokinetic model for pyrazinamide was a one-compartment distribution model with absorption transit compartments, first-order absorption and elimination. The final parameter estimates are shown in Table 3 . No significant covariate relationships were supported by the data. IIV, expressed as %CV, was supported for CL (27%), while IOV was significant for CL (26%), k a (86%), F (25%) and MTT (112%). The residual error model was proportional (10% for Cohort 1 and 6% for Cohort 2). The VPC for the final model is displayed in Figure 2 , showing that the final model described the data well. The typical values of CL and V c were 3.9 L/h and 54 L, respectively, when scaled to a 70 kg individual.
Isoniazid
A total of 715 concentration -time data points were available for all 76 children. 7, 15 A two-compartment distribution model with absorption transit compartments and first-order elimination best described the pharmacokinetics of isoniazid. The final parameter estimates are shown in Table 4 . The NAT2 genotype was a significant covariate for CL and F. The OFV improved by 55.7 points when including the acetylator status, which explained 45% of the IIV in CL. Estimation of F for intermediate and fast acetylators (relative to slow acetylators) and accounting for age maturation of CL further improved the OFV by 11 and 16 points, respectively. The age maturation explained 6% IIV in CL. With respect to intermediate acetylators (CL ¼ 8.94 L/h), slow acetylators had 50% lower CL (4.44 L/h), while fast acetylators had 26% higher CL (11.3 L/h). Also, F in intermediate and fast acetylators was estimated to be 77.2%, which is 23% lower than in slow acetylators. Thus, combining the genotype effect on CL and bioavailability, the value of CL/F is 4.44, 11.6 and 14.6 L/h for slow, intermediate and fast acetylators, respectively. The final model included IIV, expressed as %CV, in CL (25%) and IOV in k a (61%), MTT (94%) and F (40%). The maturation of CL is represented in Figure 1 and the VPC for the final model is shown in Figure 2 . When scaled to a 70 kg individual, the typical values of CL (not CL/F, so before adjusting for the effect of NAT2 genotype on F) were 16.2, 32.5 and 41.1 L/h for slow, intermediate and fast acetylators, respectively, and V c and V p were 61.6 and 28.2 L.
Simulations
Using the final models and WHO's newly recommended higher dosages utilizing revised FDC recommendations, the predicted steady-state AUCs for all weight bands are shown in Figures 3 -5 for rifampicin, pyrazinamide and isoniazid, respectively. Median rifampicin exposures were similar to those in adults, although wider variability was present in the simulated paediatric Population pharmacokinetics of antituberculosis drugs in children 1343
JAC
Discussion
We described the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in South African children treated for tuberculosis. In addition, drug exposures resulting from the dosages recently recommended by the WHO were investigated. Our simulations predicted that, even with the increased dosages, smaller children would achieve relatively low exposures to pyrazinamide and isoniazid. Moreover, intermediate and fast acetylators (together comprising 61% of our population) may be underdosed with respect to isoniazid if exposures in an ethnically similar population of adults are considered therapeutic ( Figure 5 ). It should be noted that the doses of pyrazinamide and isoniazid used for these predictions tended to be somewhat lower than the recommended dose per kg, especially in the youngest children. Our choice of weight bands was based on ongoing discussions about the optimal dose of the FDC by weight band, pragmatic considerations, such as the stability and equal distribution of active ingredients in each portion after breaking the FDC tablets, and concern that pharmacokinetic maturation could still be incomplete in young children. 9, 32, 33 Our proposed doses were optimized assuming that dividing the FDC tablets should be avoided if possible.
The typical paediatric parameter estimates for rifampicin CL/F and V c /F are in line with adult values reported in an ethnically similar population. 24 After adjusting for the difference in body size (the median weight of the adult population used for comparison was 50 kg), CL/F was 23.1 L/h in children versus 19.2 L/h in adults and V c /F was 64.8 versus 53.2 L, respectively. This suggests that pharmacokinetic differences between children and adults could mainly be explained by differences in body size (which was accounted for by allometric scaling in our models) and enzyme maturation. Our data did not support non-linearity in the pharmacokinetics of rifampicin, even though the doses given ranged from 5 to almost 18 mg/kg daily. Our results therefore suggest that at the doses used in the children studied, rifampicin may not display the dose-dependent non-linear pharmacokinetics in children that has been described in adults. 34 However, further studies, including sufficient numbers of children being given the increased dosages, would be needed to confirm this. Low rifampicin concentrations are associated with the development of acquired rifamycin monoresistance (ARR) 35 and a C max of 8 mg/L has been suggested for rifampicin, 36 although even higher concentrations are likely necessary for maximal bactericidal activity. 6 However, such concentrations are rarely achieved in children prescribed 8 -12 mg/kg/day doses of rifampicin. 8 If the pharmacokinetics in an ethnically similar adult population 24 Zvada et al.
given the currently recommended doses is used for comparison, the majority of our children fall within the 5th -95th percentile range of exposures in the adult patients ( Figure 3) . The simulated adult exposures were similar to those found in a large pharmacokinetic study conducted in adults with pulmonary tuberculosis in Botswana. 37 Our simulations for children using the newly recommended WHO paediatric guidelines predicted more variable rifampicin exposures than those for the reference adult population (Figure 3) . Moreover, both the predicted mean C max using the revised paediatric guidelines (6.6 mg/L) and the current doses recommended by WHO in the adult reference population (4.8 mg/L) were lower than the proposed minimum C max of 8 mg/L, 36 implying that even higher doses of rifampicin should be considered for both children and adults.
Using the final pyrazinamide model and parameter estimates for CL/F and V c /F scaled to the median weight of the adult population used for comparison (51.5 kg), 30 the children had similar CL/F ( 3.1 versus 3.42 L/h) and higher V c /F (39.7 versus 29.2 L) compared with the adults. The higher V c /F in children could partly be due to malnutrition and severe forms of tuberculosis disease. When we targeted previously reported exposures in an ethnically similar adult population who received doses recommended by WHO, our simulation results predicted that children weighing 5.0 -7.9 kg may be underdosed ( Figure 4 ). As noted above, Population pharmacokinetics of antituberculosis drugs in children 1345 JAC children in the lowest weight band tended to receive doses somewhat lower than the 30 -40 mg/kg target proposed in the revised guidelines. Our simulations suggest that a 50 mg/kg dose for children in the lowest weight band of 5.0 -7.9 kg would achieve the same median AUC as that in the adults. The pyrazinamide exposures we simulated for our reference adult population were similar to those in the large cohort in Botswana. 37 In addition, the majority of adults had simulated C max within the suggested range of 20 -50 mg/L. 36 Importantly, patients in the Botswana cohort with pyrazinamide C max ,35 mg/L had an increased risk of poor treatment outcome.
Isoniazid pharmacokinetics is highly dependent on the polymorphic NAT2, which is a major determinant of isoniazid plasma concentrations. 38 Targeting average exposures simulated for ethnically similar adults following doses currently recommended by WHO, the new doses recommended by the WHO for children are adequate for slow acetylators, but insufficient for intermediate and fast acetylators ( Figure 5 ). We have noted wide IIV in the systemic concentrations and AUC mostly because children were not dosed according to the NAT2 acetylator genotype. Hence, further studies are needed to adequately define the implications of IIV for safety and efficacy in children. Interestingly, children who were younger than 1 year old had higher AUC irrespective of their weight band. In addition, isoniazid CL showed maturation with age and this supports the notion that finer weight bands in conjunction with age should be considered to avoid overdosing very young children. Zvada et al.
increased pre-systemic metabolism, which also correlates with systemic clearance. The lower exposure in intermediate and fast acetylators may predispose to the development of ARR. In the CDC Study 22, 39 an association was found between low isoniazid plasma concentrations and the occurrence of relapse in patients on a regimen of once-weekly rifapentine and isoniazid, suggesting that isoniazid might have been ineffective in preventing the development of rifamycin resistance.
In all our models, we decided to scale clearance and volume with allometric scaling and this choice over using weight as a linear covariate was also supported by the data following general criteria such as the NONMEM OFV. The use of allometrics to account for differences in pharmacokinetics due to body size is supported by both empirical observation and biological theory, as discussed in depth by Anderson and Holford. 20, 21 Although our children received similar formulations across the two cohorts, formulation is known to be an important determinant of bioavailability. 40, 41 Other factors encountered when preparing suspensions and administering the drug are likely to play a role in young children who cannot swallow tablets. There is a need for studies to evaluate such sources of variability in paediatric drug exposure and to develop solutions to reduce it. Genetic diversity Population pharmacokinetics of antituberculosis drugs in children is also an important consideration when extrapolating the results of pharmacokinetic studies. There is considerable geographical variation in the distribution of NAT2 polymorphisms. 42, 43 Moreover, recent studies have identified polymorphisms of SLCO1B1 (which encodes the OATP1B1 transporter) occurring in relatively high frequencies in African populations, associated with substantially reduced rifampicin exposure. 25, 44 Hence, pharmacogenetic studies in children may allow further optimization of dosing strategies.
Limitations of our model include the fact that the AMA values and z scores used to test anthropometric associations with the pharmacokinetic parameters were not derived specifically from an African population and thus they may not have correctly described the children in our study population. Finally, a limitation of our simulation approach is that it does not account for any nonlinearity in the pharmacokinetics that may occur at the higher doses; hence, our predictions should be confirmed in pharmacokinetic studies in children dosed according to the revised guidelines.
In conclusion, our models describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis. Simulations based on our models predict that the newly recommended weight band-based doses in WHO guidelines for children result in rifampicin exposures in our paediatric population that are similar to those in adults. However, when dosed in pragmatic weight bands, there is wide variability in drug exposure and pyrazinamide and isoniazid exposures in many children will be lower than those in an ethnically similar adult population. Hence, adjustment of the recommended doses may be warranted should the findings be confirmed in other populations.
